Teva Pharmaceuticals Industries Ltd. announced that it has filed Abbreviated New Drug Application No.209522 with the United States Food and Drug Administration seeking regulatory approval to market a generic version of NARCAN (naloxone hydrochloride) Nasal Spray (NARCAN) before the expiration of U.S. Patent o. 9,468,747. The 747 patent is listed with respect to NARCAN in the FDA's Approved Drug Products with Therapeutic Equivalents Evaluations publication and expires on March 16, 2035.